Skip to main content

Saniona AB’s Nomination Committee for the Annual General Meeting 2020

Written by Customer Service on . Posted in Public Companies.

PRESS RELEASENovember 27, 2019The Annual General Meeting on May 29, 2019, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors.
On September 30, 2019, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB’s Nomination Committee.The Nomination Committee’s member are:Søren Skjærbæk, Partner at Ursus law firm, Vejle, Denmark, appointed by Jørgen DrejerJohn Haurum, professional board member for life science companies and former CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Thomas FeldthusJ. Donald deBethizy, Chairman of Saniona AB’s BoardThe Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2020 regarding:election of the Chairman at the Annual General Meetingelection of the Chairman and other members of the Board;remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work;election of the auditor and the auditor’s remuneration; andprinciples for appointing the Nomination Committee.The instruction and charter for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company’s website, www.saniona.com.Saniona AB’s Annual General Meeting will be held on Wednesday May 27, 2020 in Malmö.Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to tf@saniona.com marked “Recommendation to the Nomination Committee” or by ordinary mail to the address:            Recommendation to the Nomination Committee
            Saniona AB
            Att. Thomas Feldthus
            Baltorpvej 154
            DK-2750 Ballerup
            DenmarkTo ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 17, 2020.For more information, please contactThomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 8 a.m. CET on November 27, 2019.About SanionaSaniona is a research and development company focused on drugs for treatment of eating disorders and diseases of the central nervous system. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.Attachment20191127 – PR – Nomination Committee – UK

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.